{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:25Z","timestamp":1761896125180,"version":"build-2065373602"},"reference-count":9,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T00:00:00Z","timestamp":1341792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Bristol-Myers Squibb"},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,12]]},"abstract":"\n Saxagliptin (Onglyza\u2122) is a dipeptidyl peptidase\u20104 (\n DPP4<\/jats:styled-content>\n ) inhibitor for treating type 2 diabetes mellitus. This open\u2010label, randomized, two\u2010way crossover study in 20 healthy female subjects investigated the effect of saxagliptin on the pharmacokinetics (\n PK<\/jats:styled-content>\n ) of the active components of a combined oral contraceptive (\n COC<\/jats:styled-content>\n ). Subjects received either\n COC<\/jats:styled-content>\n (Ortho\u2010Cyclen\n \u00ae<\/jats:sup>\n ) once daily (\n QD<\/jats:styled-content>\n ) for 21\u2009days, then 5\u2009mg saxagliptin\n QD<\/jats:styled-content>\n +\n COC QD<\/jats:styled-content>\n for 21\u2009days, or vice versa. Coadministration of saxagliptin and\n COC<\/jats:styled-content>\n did not alter the steady\u2010state\n PK<\/jats:styled-content>\n of the primary active oestrogen (ethinyl estradiol) or progestin (norelgestromin)\n COC<\/jats:styled-content>\n components. The area under the concentration\u2013time curve (\n AUC<\/jats:styled-content>\n ) and peak plasma concentration (C\n max<\/jats:sub>\n ) of an active metabolite of norelgestromin (norgestrel) were increased by 13 and 17%, respectively, a magnitude that was not considered clinically meaningful. Coadministration of saxagliptin and\n COC<\/jats:styled-content>\n in this study was generally well\u2010tolerated. Saxagliptin can be co\u2010prescribed with an oestrogen\/progestin combination for women taking oral contraceptive.\n <\/jats:p>","DOI":"10.1111\/j.1463-1326.2012.01635.x","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T16:03:30Z","timestamp":1341590610000},"page":"1155-1157","source":"Crossref","is-referenced-by-count":3,"title":["Effect of saxagliptin on the pharmacokinetics of the active components of Ortho\u2010Cyclen\n \u00ae<\/sup>\n , a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women"],"prefix":"10.1111","volume":"14","author":[{"given":"V. V.","family":"Upreti","sequence":"first","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company (BMS) Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. B.","family":"Hsiang","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company (BMS) Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Li","sequence":"additional","affiliation":[{"name":"Global Biometric Sciences BMS Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Xu","sequence":"additional","affiliation":[{"name":"Bioanalytical Sciences BMS Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P.","family":"LaCreta","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company (BMS) Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Boulton","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Company (BMS) Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2008.06.008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.11.1663"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2004.06.001"},{"key":"e_1_2_7_5_1","first-page":"1","article-title":"Use of contraception and use of family planning services in the United States: 1982\u20132002","volume":"10","author":"Mosher WD","year":"2004","journal-title":"Adv Data"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e318159c06a"},{"key":"e_1_2_7_7_1","first-page":"1","article-title":"Oral contraceptives \u2013 an update","volume":"28","author":"Blackburn RD","year":"2000","journal-title":"Popul Rep A"},{"key":"e_1_2_7_8_1","unstructured":"Ortho\u2010Cyclen\u00ae(norgestimate\/ethinyl estradiol) Tablets. [Prescribing information]. Ortho\u2010McNeil Pharmaceutical Inc. Raritan NJ USA August2007."},{"key":"e_1_2_7_9_1","unstructured":"Onglyza[package insert]. Bristol\u2010Myers Squibb Co. Princeton NJ USA July2009."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70120-1"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2012.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2012.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:09:02Z","timestamp":1761890942000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2012.01635.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,9]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1463-1326.2012.01635.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01635.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2012,7,9]]}}}